DAWN Valuation

Day One Biopharmaceuticals Inc

Add to Watchlist

Advanced Chart

7.510

-0.08(-1.054%)1D

Overview
Forecast
Valuation
Earnings

DAWN Relative Valuation

DAWN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DAWN is overvalued; if below, it's undervalued.

Historical Valuation

Day One Biopharmaceuticals Inc (DAWN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.30 is considered Undervalued compared with the five-year average of -8.04. The fair price of Day One Biopharmaceuticals Inc (DAWN) is between 27.62 to 37.57 according to relative valuation methord. Compared to the current price of 7.49 USD , Day One Biopharmaceuticals Inc is Undervalued By 72.9%.

Relative Value

Fair Zone

27.62-37.57

Current Price：7.49

72.9%

Undervalued

-6.53

Trailing

Forward

-2.45

EV/EBITDA

Day One Biopharmaceuticals Inc. (DAWN) has a current EV/EBITDA of -2.45. The 5-year average EV/EBITDA is -5.35. The thresholds are as follows: Strongly Undervalued below -14.23, Undervalued between -14.23 and -9.79, Fairly Valued between -0.91 and -9.79, Overvalued between -0.91 and 3.52, and Strongly Overvalued above 3.52. The current Forward EV/EBITDA of -2.45 falls within the Historic Trend Line -Fairly Valued range.

-2.58

EV/EBIT

Day One Biopharmaceuticals Inc. (DAWN) has a current EV/EBIT of -2.58. The 5-year average EV/EBIT is -5.18. The thresholds are as follows: Strongly Undervalued below -12.20, Undervalued between -12.20 and -8.69, Fairly Valued between -1.66 and -8.69, Overvalued between -1.66 and 1.85, and Strongly Overvalued above 1.85. The current Forward EV/EBIT of -2.58 falls within the Historic Trend Line -Fairly Valued range.

4.30

Day One Biopharmaceuticals Inc. (DAWN) has a current PS of 4.30. The 5-year average PS is 507.26. The thresholds are as follows: Strongly Undervalued below -3300.27, Undervalued between -3300.27 and -1396.51, Fairly Valued between 2411.02 and -1396.51, Overvalued between 2411.02 and 4314.78, and Strongly Overvalued above 4314.78. The current Forward PS of 4.30 falls within the Historic Trend Line -Fairly Valued range.

-6.86

P/OCF

Day One Biopharmaceuticals Inc. (DAWN) has a current P/OCF of -6.86. The 5-year average P/OCF is -10.75. The thresholds are as follows: Strongly Undervalued below -19.64, Undervalued between -19.64 and -15.19, Fairly Valued between -6.31 and -15.19, Overvalued between -6.31 and -1.86, and Strongly Overvalued above -1.86. The current Forward P/OCF of -6.86 falls within the Historic Trend Line -Fairly Valued range.

-9.60

P/FCF

Day One Biopharmaceuticals Inc. (DAWN) has a current P/FCF of -9.60. The 5-year average P/FCF is -11.46. The thresholds are as follows: Strongly Undervalued below -24.37, Undervalued between -24.37 and -17.91, Fairly Valued between -5.00 and -17.91, Overvalued between -5.00 and 1.45, and Strongly Overvalued above 1.45. The current Forward P/FCF of -9.60 falls within the Historic Trend Line -Fairly Valued range.

Day One Biopharmaceuticals Inc (DAWN) has a current Price-to-Book (P/B) ratio of 1.69. Compared to its 3-year average P/B ratio of 3.19 , the current P/B ratio is approximately -47.10% higher. Relative to its 5-year average P/B ratio of 3.23, the current P/B ratio is about -47.84% higher. Day One Biopharmaceuticals Inc (DAWN) has a Forward Free Cash Flow (FCF) yield of approximately -8.43%. Compared to its 3-year average FCF yield of -10.38%, the current FCF yield is approximately -18.80% lower. Relative to its 5-year average FCF yield of -8.81% , the current FCF yield is about -4.37% lower.

1.69

P/B

Median3y

3.19

Median5y

3.23

-8.43

FCF Yield

Median3y

-10.38

Median5y

-8.81

Competitors Valuation Multiple

The average P/S ratio for DAWN's competitors is 55.89, providing a benchmark for relative valuation. Day One Biopharmaceuticals Inc Corp (DAWN) exhibits a P/S ratio of 4.30, which is -92.31% above the industry average. Given its robust revenue growth of 313.92%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DAWN.O

Day One Biopharmaceuticals Inc

Gyre Therapeutics Inc

Rigel Pharmaceuticals Inc

Theravance Biopharma Inc

Mind Medicine (MindMed) Inc

Loss

675.66M

ABUS.O

Arbutus Biopharma Corp

315.92

522.19%

711.20M

Performance Decomposition

Market capitalization of DAWN decreased by 45.74% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 8.19M to 33.91M.

The secondary factor is the Margin Expansion, contributed 66.21%to the performance.

Overall, the performance of DAWN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

313.92%

8.19M → 33.91M

Revenue Growth

66.21%

-53.80 → -89.42

Margin Expansion

-425.87%

2.46 → -8.00

P/E Change

-45.74%